1. Telfer NR, Colver GB, Bowers PW. Guidelines for the management of basal cell carcinoma. Br J Dermatol 1999;141:415-23.
2. Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med 1992;327:1649-62.
3. Miller SJ. Biology of basal cell carcinoma (part 1). J Am Acad Dermatol 1991;24:1-13.
4. Goodwin RG, Roberts, DL. Skin cancer registration in the United Kingdom. Br J Dermatol 2001;145(Suppl. 59):17.
5. Walberg P, Skog E. The increasing incidence of basal cell carcinoma. Br J Dermatol 1994;131:914-15.
6. Holme SA, Malinovszky K, Roberts DL. Changing trends in non-melanoma skin cancer in South Wales, 1988-98. Br J Dermatol 2000; 143:1224-9.
7. Chuang TY, Popescu A, Su WP, Chute CG. Basal cell carcinoma: a population-based incidence study in Rochester, Minnesota. J Am Acad Dermatol 1990;22: 413-17.
8. Marks R, Staples M, Giles GG. Trends in non-melanocytic skin cancer treated in Australia: the second national survey. Int J Cancer 1993;53:585-90.
9. Roenigk RK, Ratz JL, Bailin PL, Wheeland RG. Trends in the presentation and treatment of basal cell carcinomas. J Dermatol Surg Oncol 1986;12:860-5.
10. McCormack CJ, Kelly JW, Dorevitch AP. Differences in age and body site distribution of the histological subtypes of basal cell carcinoma:a possible indicator of differing causes. Arch Dermatol 1997;133:593-6.
11. Gilbody JS, Aitken J, Green A. What causes basal cell carcinoma to be the commonest cancer? Aust J Public Health 1994;18:218-21.
12. Zaynoun S, Ali LA, Shaib J. The relationship of sun exposure and solar elastosis to basal cell carcinoma. J Am Acad Dermatol 1985; 12:522-5.
13. Pearl DK, Scott EL. The anatomical distribution of skin cancers. Int J Epidemiol 1986;15:502-6.
14. Mackie RM, Elwood JM, Hawk JLM. Links between exposure to ultraviolet radiation and skin cancer. A report of the Royal College of Physicians. J R Coll Phys Lond 1987;21:91-6.
15. Schreiber MM, Moon TE, Fox SH, Davidson J. The risk of developing subsequent nonmelanoma skin cancers. J Am Acad Dermatol 1990;23:1114-18.
16. Johnson RL, Rothman AL, Xie J et al. Human homolog of patched, a candidate gene for the Basal Cell Nevus Syndrome. Science 1996;272:1668-71.
17. Staples M, Marks R, Giles G. Trends in the incidence of non-melanocytic skin cancer (NMSC) treated in Australia 1985-1995: are primary prevention programs starting to have an effect? Int J Cancer 1998;78:144-8.
18. Breuninger H, Deitz K. Prediction of subclinical tumour infiltration in basal cell carcinoma. J Dermatol Surg Oncol 1991;17:574-8.
19. Gussack GS. Schlitt M. Lushington A. Woods KE. Invasive basal cell carcinoma of the temporal bone. Ear Nose Throat J 1998;68:605-6;609-11.
20. Franchimont C. Episodic progression and regression of basal cell carcinomas. Br J Dermatol 1982;106:305-10.
21. Takenouchi T, Nomoto S, Ito M. Factors influencing the linear depth of invasion of primary basal cell carcinoma. Dermatol Surg 2001;27:393-6.
22. Clark M, Oxman AD eds. Optimat search strategy for RCTs. In: Cochrane Reviewers' Handbook 4.1 (updated June 2000). Cochrane Collaboration. Oxford, 2000: appendix 5c.
23. Dubin N, Kopf AW. Multivariate risk score for recurrence of cutaneous basal cell carcinoma. Arch Dermatol 1983;119:373-7.
24. Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol 1987;123:340-4.
25. Avril MF, Auperin A, Margulis A et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomised study. Br J Cancer 1997;76:100-6.
26. Petit JY, Avril MF et al. Evaluation of cosmetic resulls of a randomised trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plas Reconstr Surg 2000; 105:2544-51.
27. Rowe DE, Carroll RJ, Day CL Jr. Long term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow up. J Dermatol Surg Oncol 1989;15:315-28.
28. Hall VL, Leppard BJ, McGill J et al. Treatment of basal cell carcinoma: Comparison of radiotherapy and cryotherapy. Clin Radiol 1986;37:33-4.
29. Mallon E, Dawber R. Cryosurgery in the treatment of basal cell carcinoma. Dermatol Surg 1996;22:854-8.
30. Thissen MRTM, Nieman FHM, Ideler AHLB, Berretty PJM, Neumann HAM. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg 2000;26:759-64.
31. Wang I, Bendsoe N, Klinteberg CA et al. Photodynamic therapy v cryosurgery of basal cell carcinomas: results of phase III clinical trial. Br J Dermatol 2001;144: 832-40.
32. Soler AM, Angell-Petersen E, Warloe T et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacitic acid: A comparison of two light sources. Photochem Photobiol2000;71:724-9.
33. Clark C. Randomised trial of minimal curettage and topical 5-aminolaevulinic acid (5-ALA) photodynamic therapy (PDT) compared with excision for the treatment of basal cell carcinomas with low recurrence risk. Ongoing trial. Photobiology Unit, Ninewells Hospital and Medical School, Tayside University Hospitals NHS Trust, Dundee UK.
34. Alpsoy E, Yilmaz E, Basaran E, Yazar S. Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma. J Dermatol 1996;23:394-6.
35. Cornell RC, Greenway HT, Tucker SB et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 1990;23:694-700.
36. Edwards L, Tucker SB. The effects of an intralesional sustained release formulation of interferon alfa2b on basal cell carcinomas. Arch Dermatol 1990;126:1029-32.
37. Rogozinski TT, Jablonska S, Brzoska J, Michalska I, Wohr C, Gaus W. Intralesional treatment with recombinant interferon beta is an effective alternative for the treatment of basal cell carcinoma. Double-blind, placebo-controlled study. Przeglad Dermatol 1997;84:259-63.
38. Punjabi S, Cook IJ, Kersey P et al. A double-blind, multicentric parallel group study of BEC-5 cream in basal cell carcinoma (BCC). Eur Acad Dermatol Venereol 2000;14(Suppl 1):47-60.
39. Fluorouracil. In: McEvoy GK, ed. American Hospital Formulacy Service Drug Information. Bethesda, MD: American Society of Hospital Pharmacists, 1993:573-7.
40. Romagosa R, Saap L, Givens M et al. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatol Surg 2000;26:338-40.
41. Miller BH, Shavin JS, Cognetta A et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. J Am Acad Dermatol 1997;36:72-7.
42. Orenberg EK, Miller BH, Greenway HT. The effect of intralesional 5-fluorouracil therapeutic implant (MPI 5003) for treatment for basal cell carcinoma. Acad Dermatol 1992;27:723-8.
43. Testerman TL, Gerster JF, Imbertson LM et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995;58:365-72.
44. Slade HB, Owens ML, Tomai MA, Miller RL. Imiquimod 5% cream. Exp Opin Invest Drugs 1998;7:437-49.
45. Imbertson LM, Beaurline JM, Couture AM et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998; 110:734-9.
46. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM Jr. Treatment of genital warts with an immune response modifier imiquimod. J Am Acad Dermatol 1998;38:230-9.
47. Beutner KR 2, Tyring SK, Trofatter KR et al. Imiquimod, a patient applied immune response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998;42:788-94.
48. Edwards L, Ferenczy A, Eron L et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998;134:25-30.
49. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999;41:1002-7.
50. Bavinck JN. Biological treatment of basal cell carcinoma. Arch Dermatol2000;136:774-5.
51. Marks R, Gebauer K, Shumak S et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001;44:807-13.
52. Geisse JK, Marks R, Owens ML, Andres K, Ginkel AM. Imiquimod 5% cream for 12 weeks treating superficial BCC. Abstract P58 at 8th World Congress on Cancers of the Skin, Zurich, Switzerland 18th-21st July 2001.
53. Sterry W, Bichel J, Andres K, Ginkel AM. Imiquimod 5% cream for 6 weeks with occlusion treating superficial BCC. Abstract P61 at 8th World Congress on Cancers of the Skin, Zurich, Switzerland 18th-21st July 2001.
54. Robinson JK, Marks R, Owens ML, Andres K, Ginkel AM. Imiquimod 5% cream for 12 weeks treating nodular BCC. Abstract P57 at 8th World Congress on Cancers of the Skin, Zurich, Switzerland 18th-21st July 2001.
55. Shumak S, Marks R, Amies M, Andres K, Ginkel AM. Imiquimod 5% cream for 6 weeks treating nodular BCC. Abstract P55 at 8th World Congress on Cancers of the Skin, Zurich, Switzerland 18th-21st July 2001.
Was this article helpful?
Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.